Imatinib

Liver Fibrosis

Research Institute for Gastroenterology and Liver Diseases (RIGLD)Small moleculePhase 1/2Dormant

CC

47/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 89/ 100

Competitive context

27 Active assets in the Liver Fibrosis cohort.

Asset / Sponsor	Phase	Rating
Entecavir Tanta University	Phase 4	BB
COLCHICINUM Zagazig University	Phase 4	BB
Peg-Intron Beth Israel Deaconess Medical Center	Phase 4	BB
Peg-Ifn Beijing Friendship Hospital	Phase 4	BB
Hydronidone Beijing Continent Pharmaceutical Co, Ltd.	Phase 3	BB

View all 50 →

Same molecule, other indications

Imatinib is also rated in:

chronic myeloid leukemiaDormant

BB

Indicative ·

71 / 100

blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant

BB

Indicative ·

71 / 100

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.